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1. Introduction 
The past decade has witnessed enormous advances in understanding the association 
between arterial hypertension and renal disease. This chapter aims to provide a 
comprehensive review about new insights generated from recent experimental and clinical 
studies that should shed light on the role of the kidney in causing hypertension but also the 
role of hypertension in causing renal disease. It will focus on pathogenic mechanisms that 
connect arterial hypertension with target renal damage and new markers able to identify 
subclinical target-renal damage.   
Nowadays, the most important causes of renal failure and dialysis in the world arterial are 
hypertension and diabetes mellitus. The kidneys have a central role in the control of sodium 
homeostasis through the important mechanism of regulation of blood pressure. Arterial 
hypertension is also a well known consequence of chronic kidney disease (CKD), and at the 
same time one of the main factors causing diabetic and/or non-diabetic chronic renal failure 
progression (Ljutić, 2003).  
Kidneys can be damaged by arterial hypertension by several mechanisms. Because 
autoregulation of glomerular pressure is impaired in CKD, elevations in systemic blood 
pressure are associated with increased glomerular capillary pressure. Glomerular 
hypertension results in increased protein filtration and endothelial damage, causing 
increased release of cytokines and other soluble mediators, promoting replacement of 
normal kidney tissue by fibrosis. An important factor contributing to progressive renal 
disease is activation of the renin-angiotensin system, which tends to increase blood pressure 
and also promotes cell proliferation, inflammation, and matrix accumulation (Dworkin, 
1999). An important part of the standard of care in clinics is the evaluation of 
microalbuminuria in order to detect renal organ damage that may influence the occurrence 
of future cardiovascular events.  Screening for renal organ damage is part of classification 
schemes and clinical assessment process and influences the therapy to prevent disease 
progression and delay or prevent future cardiovascular events. The presence of target organ 
damage defines a high-risk population that develops complications due to suboptimal 
disease control or accelerated development and progression of the atherosclerotic process 
(Lockhart, 2009).  
The renin-angiotensin system (RAS) is the most important mechanism for blood pressure 
regulation and electrolyte homeostasis. It was suggested that the major fraction of 
angiotensin II present in renal tissues is locally generated from angiotensinogen delivered to 
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the kidney as well as from angiotensinogen locally produced by the proximal tubule cells 
(Kobori, 2007). Renin is produced by the cells of the juxtaglomerular apparatus cells and 
then delivered in the renal interstitium and vascular compartment resulting local generation 
of angiotensin. Angiotensin-converting enzyme is abundant in the kidney and is present in 
the proximal tubules, distal tubules, and collecting ducts (Kobori, 2010). Angiotensin I 
delivered to the kidney can also be converted to angiotensin II (Komlosi, 2003). All of the 
components necessary to generate intrarenal angiotensin II are present along the nephron 
(Navar, 2002; Kobori, 2007). Recently, in the Bogalusa Heart Study was proved that urinary 
level of angiotensinogen can be a new and potential marker of intrarenal RAS status in 
kidney disease due to arterial hypertension (Kobori, 2010). An important role in progression 
of inflammation and fibrosis seems to involve the renin-angiotensin system, and specifically 
the angiotensin-converting enzyme (ACE)-angiotensin (Ang) II-AT1 receptor axis. ACE2, a 
new component of the renin-angiotensin system, has emerged as a key enzyme that 
selectively degrades Ang II and generates Ang-(1-7), a bioactive peptide with anti-
inflammatory and anti-fibrotic actions (Chappell, 2010). The deficiency of angiotensin-
converting enzyme 2 is associated with elevated tissue and circulating levels of angiotensin 
II, reduced levels of angiotensin and progressive glomerulosclerosis in the kidneys (Tikellis, 
2011). Definitely, the overexpression of angiotensin-converting enzyme 2 may produce 
adverse cardiac effects, and angiotensin-converting enzyme 2 and its metabolic products 
may promote epithelial-to-mesenchymal transition (Tikellis, 2011). 
Increased activity of the intrarenal RAS is another concept considered responsible for initiating 
and maintaining an elevated blood pressure in patients with hypertension and it is 
sustained by a lot of studies (Mitchell, 1992; Navar, 1999; Navar, 2002; Guyenet, 2006; 
Kobori, 2007). 
Since current European guidelines on hypertension (Mancia, 2007), stratify individuals 
based on both known risk factors and early markers of subclinical target-organ damage, the 
chapter focuses further on new and old available biomarkers that can detect renal damage in 
arterial hypertension. Blood urea nitrogen and creatinine clearance are well-established 
biomarkers of renal function that can be measured cheaply and easily. Reduced glomerular 
filtration rate (GFR) and increased urinary albumin excretion are manifestations of target 
organ damage in hypertension. New renal biomarkers include: urinary level of 
angiotensinogen, plasma aldosterone concentration, hyperhomocysteinemia and cystatin C.  
Antihypertensive agents like diuretics, angiotensin converting enzyme (ACE) inhibitors, 
angiotensin II (Ang II) receptor antagonists, ß-blockers, or calcium channel blockers (CCBs) 
can improve end organ damage and effectively reduce hypertension (Cohuet, 2006). 
2. From arterial hypertension to renal organ damage  
The increasing prevalence of arterial hypertension in general population is caused by a sum 
of factors involved in renal disease progression like atherogenic dyslipidemia, metabolic 
syndrome, type II diabetes, anemia, and disorders of mineral metabolism.  
The first form of hypertension most commonly observed in early or borderline hypertension 
is characterized by salt-resistance, normal or only slightly decreased GFR, relatively normal 
or mild renal arteriolosclerosis, and normal renal autoregulation. The patients affected by 
this form of hypertension are at minimal risk for renal progression.  
The second form of hypertension, characterized by salt-sensitivity, renal arteriolar disease, 
and blunted renal autoregulation, defines a group at highest risk for the development of 
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microalbuminuria, albuminuria, and progressive renal disease. This second form is more 
likely to be observed in blacks, in subjects with gout or hyperuricemia, with low level lead 
intoxication, or with severe obesity/metabolic syndrome (Johnson, 2005). 
Essential hypertension is frequently associated with arteriolar thickening, fibrinoid 
deposition in the glomeruli, and proteinuria (Cohuet, 2006). The deleterious effects of 
systemic hypertension on renal vascular bed depend on the degree to which the 
microcirculation is exposed to elevated pressures. Renal injury occurs when the 
preglomerular autoregulatory mechanism is insufficient to maintain flow and pressure in 
the kidney (Griffin, 2003). 
Chronic hypertension can lead to nephrosclerosis, a common cause of CKD (Porth, 2011). 
Clinicians use different terms to identify renal damage caused by hypertension like 
nephrosclerosis, benign nephrosclerosis, hypertensive kidney disease, or 
nephroangiosclerosis. Two clinicopathologic patterns have been described until now. The 
first form is benign nephrosclerosis or simply nephrosclerosis, characterised by microvascular 
changes with hyalinosis of the preglomerular vessel walls and thickening of the intima and 
reduplication of the internal elastic lamina of the arcuate and interlobar arteries. These 
modifications can lead to glomerular damage, glomerulosclerosis, patchy tubular atrophy, 
and interstitial fibrosis. The second form is malignant nephrosclerosis, associated with 
accelerated or malignant hypertension, characterized by fibrinoid necrosis and myointimal 
hyperplasia and left untreated can cause progressive renal insufficiency. It becomes a rare 
entity today due to improvements of antihypertensive management (Marin, 2005). Brenner 
established the central role for nephron injury and loss in glomerular hypertension. The 
remaining nephrons develop glomerular capillary hypertension accompanied with 
hyperfiltration (Brenner, 1982). Nephrosclerosis has actually been seen as a form of 
intrarenal renovascular disease (Marín, 2005). Beside benign and malignant nephrosclerosis, 
the spectrum of hypertension-induced renal damage is larger. The pathogenetic 
mechanisms involved in hypertensive renal damage seems to be the systemic blood 
pressure “load”, the degree to which such load is transmitted to the renal vascular bed and 
the local tissue susceptibility to any given degree of barotrauma (Bidani, 2004).  
In 2009 was proposed a new theory about nephrosclerosis induced by hypertension that 
involves the genetic MYH9 polymorphisms. The presence of MYH9 polymorphisms in 
individuals leads to products that disrupt normal podocyte function, causing podocyte 
injury, which ultimately leads to glomerulosclerosis (Freedman, 2009). The presence of 
genetic polymorphisms leading to intrinsic kidney injury suggest that the failure of strict 
blood-pressure control to prevent CKD progression does not relate to blood pressure alone, 
but rather relates to factors intrinsic to the kidney that are yet to be defined. In African 
American Study of Kidney Disease (AASK) could be observed that blood-pressure control 
alone cannot reverse existing kidney damage or stop progressive kidney damage (AASK) 
(Appel, 2008). 
Tubulointerstitial injury seems to be one of the main histological determinants of 
hypertension-related kidney damage. This fact is of particular importance because the 
pathology correlates with the degree and progression of renal impairment, regardless of the 
type and origin of kidney injury. Long time it was supposed that interstitial and tubular 
damage is secondary to glomerular and vascular injury and occurs in the final stages of 
hypertensive nephropathy. However, experimental studies have demonstrated that this 
type of kidney damage can be present in hypertensive patients before any changes in 
glomerular vessels (Mai, 1993). Considering the results of these studies, it may be 
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hypothesized that the tubulointerstitium may be an initial site of renal injury in primary 
hypertension. This hypothesis is based only on animal studies, however, and has not been 
finally confirmed in clinical research (Tylicki, 2003). 
Endothelium seems to be at the crossroads of the risk for renal impairment and 
cardiovascular complications in individuals with essential hypertension, therefore, 
combined effects of low-grade inflammation, oxidative stress and hyperuricemia may be the 
link between arterial hypertension and renal organ damage. Different studies showed that 
endothelial dysfunction is associated with renal function decline in hypertensive patients 
with normal or only mildly impaired baseline renal function (Perticone, 2010). It is possible 
that a reduction of GFR could induce endothelial dysfunction, establishing a vicious circle 
which, if not interrupted, promotes the progression of both renal and vascular damage. 
Therefore, systemic endothelial dysfunction represents an important physiopathological 
mechanism for the appearance and progression of mild renal dysfunction in hypertensive 
status. Interstitial inflammation together with oxidative stress participates to the 
development and maintenance of hypertension by reducing the number of nephrons, 
limiting therefore the sodium filtration (Brenner, 1988). Ultimately, these effects lead to end 
stage renal disease. In hypertension, the permeability of the glomeruli is altered which leads 
to an excess of protein infiltration. The toxicity of this protein load generates tubular 
damage, inflammation and scarring (Cohuet, 2006). 
Novel biomarkers of renal damage are currently investigated and could be used to identify 
the first signs of hypertension-associated renal injury. There are a number of definitions of 
the term “biomarker”. In general, they have in common three components:  
1. They are objectively measured indicators of specific anatomic, physiologic, biochemical, 
or molecular events; 
2. They are associated with normal biological processes or accompany the onset, 
progression and/or severity of specific pathological or toxic conditions;  
3. They are useful to assess the progress of injury, disease or the effects of therapeutic 
intervention. 
2.1 Low grade inflammation 
The degree of inflammation and fibrosis of the tubulointerstitial compartment are 
considered strong predictors of the renal function loss and the risk of progression to end-
stage renal disease (Leemans, 2009). Tissue fibrosis and chronic inflammation are common 
causes of progressive renal damage, leading to loss of physiological functions. Renal 
fibrosis can be defined by the accumulation of interstitial leukocytes and fibroblasts, 
contributing to abnormal accumulation of extracellular matrix (ECM) and, eventual, 
tubular atrophy and loss of renal function (Iwano, 2004). Interestingly, the concept of 
renal inflammation in progressive kidney disease is intertwined with the concept of 
hemodynamically induced renal injury (Stuveling, 2005). In the last years, low-grade 
inflammation has acquired progressive recognition as a mechanism facilitating the 
occurrence of both glomerular and tubulo-interstitial renal damage. Recently, it was 
shown that Toll-like receptor 2 (TLR2) is expressed in the kidney and activated by 
endogenous danger signals (Leemans, 2009). The renal fibrosis is considered to be the 
common final pathway by which kidney diseases with variable etiology progresses to 
end-stage renal failure. It is therefore important to identify factors that participate in the 
initiation of tubulointerstitial inflammation and subsequent interstitial fibrosis during 
progressive renal injury. Toll-like receptor 2 (TLR2) and 4 plays a crucial role in the 
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induction of acute inflammation and early tubular injury in the kidney in a reversible 
model of acute renal injury (Leemans, 2009). 
Among inflammatory markers, high-sensitive C-reactive protein levels has been recently 
associated with early kidney damage and seems to best identify the subgroup of 
hypertensive patients at risk for renal involvement (Zoccali, 2006). Subtle elevations in 
plasma concentration of high-sensitive C-reactive protein, a reliable marker of inflammation, 
were associated with similarly subtle reductions in creatinine clearance in the Prevention of 
Renal and Vascular Endstage Disease (PREVEND) study (Stuveling, 2003). 
2.2 Oxidative stress 
The role of reactive oxygen species (ROS) has been documented in both experimental and 
human hypertension (Romero, 1999). It was observed that ROS can have direct and indirect 
effects on the vascular reactivity (Cohuet, 2006). Indeed, by inactivating endothelial nitric 
oxide, ROS impair vasodilation and can also have direct effects on vascular tone in function 
of the quantity of ROS produced and the involved vascular bed. The major ROS is the 
superoxide anion ·O2− and the most common response to its stimulus is vasoconstriction 
directly or potentiation of the constriction due to angiotensin II (Ang II), thromboxane A2, 
endothelin-1 (ET-1), and norepinephrine by increasing intracellular calcium in smooth 
muscle and endothelial cells. In addition, tubulointerstitial inflammation (infiltration and 
accumulation of lymphocytes and macrophages) appears to be responsible for the mediation 
of sodium retention in salt-sensitive models of hypertension. Moreover, oxidative stress may 
have an influence on sodium retention through tubulointerstitial accumulation of Ang II-
positive cells. These 2 mechanisms for hypertension pathogenesis are related by their effects 
on sodium retention via intrarenal Ang II activity. In the kidney, Ang II decreases 
glomerular filtration rate, increases tubular sodium reabsorption, and impairs pressure–
natriuresis contributing to renal insufficiency. Additionally, oxidative stress has 
proinflammatory effects: firstly, it activates NF-κB, a transcription factor for 
proinflammatory genes, which promotes leucocytes infiltration by increasing the expression 
of adhesion molecules and secondly, it induces the expression of heat shock proteins, 
resulting in cell death and apoptosis in an inflammatory environment.   
2.3 Hyperuricemia 
Uric acid may mediate aspects of the relationship between hypertension and kidney disease 
via renal vasoconstriction and systemic hypertension (Weiner, 2008).  Hyperuricemia is 
present in 25–40% of untreated hypertensive individuals, in 50% of those treated with 
diuretics, and in over 80% of those with malignant hypertension and is associated with 
cardiovascular disease, but is not clear if it is an independent risk factor or just a marker 
associated with cardiovascular risk factors like insulin resistance, obesity and arterial 
hypertension (Feig, 2008).  The high serum uric acid levels in hypertension have been 
attributed to several mechanisms:  
1. The reduced renal blood flow that often accompanies the hypertensive state stimulates 
urate reabsorption in the proximal tubule;  
2. The hypertensive microvascular disease leads to local tissue ischemia, the release of 
lactate that blocks urate secretion in the proximal tubule and increases uric acid 
synthesis. Tissue ischemia leads to ATP degradation to adenosine and xanthine oxidase. 
Both increased xanthine and xanthine oxidase result in increased generation of uric acid 
and oxidant (O2–) formation; 
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3. Additional factors can contribute to hyperuricemia in hypertension such as alcohol 
abuse, lead intoxication, and diuretic use.  
Animal model studies have shown that hyperuricemia activates the renin-angiotensin 
system, induces oxidative stress and reduces renal function. In experimental rat models of 
hypertension it was shown that hyperuricemia is associated with renal vasoconstriction and 
is positively correlated with plasma renin activity, these data suggest that uric acid may 
have adverse effects that are mediated by activated RAS (Lee, 2006). Few studies 
demonstrated an association between hyperuricemia and microalbuminuria in hypertensive 
patients (Viazzi, 2007). Recent studies proved that hyperuricemia predicts the development 
of new-onset kidney disease (Obermayr, 2008) and is considered a risk factor for the 
development and progression of renal disease (Kang, 2002; Johnson, 2005; Nagakawa, 2006; 
Feig, 2009). 
3. From chronic kidney disease to arterial hypertension 
Although the relationship between hypertension and CKD has been recognized for several 
hundred years, the prevalence of CKD among patients with normal blood pressure has not 
been assessed in randomly sampled populations. Crews et al reported recently that 13.4% of 
people who have normal blood pressure have CKD (Agarwal, 2010). 
From a clinical point of view, kidney diseases can be classified into two categories according 
to the onset of the renal pathology (but irrespective of the etiology of injury): (i) Acute 
kidney injury (AKI) and (ii) Chronic kidney disease (CKD).  
AKI, also known as acute renal failure or acute kidney failure, is a rapid loss of renal 
function, with variable evolution (full, partial or no recovery of a normal renal function), 
resulting in failure of urinary elimination of nitrogenous waste products (urea nitrogen and 
creatinine). This impairment of renal function results in elevations of blood urea nitrogen 
and serum creatinine concentrations. While there is no disagreement about the general 
definition of ARF, there are substantial differences in diagnosis criteria of ARF (eg, 
magnitude of rise of serum creatinine concentration). From a clinical perspective, for 
persons with normal renal function and serum creatinine concentration, GFR must be 
dramatically reduced to result in even modest increments (eg, 0.1 to 0.3 mg/dL) in serum 
creatinine concentration (Dwinnell, 1999).  
AKI and CKD affect patients worldwide and both are associated with a high morbidity and 
mortality rate (Prunotto, 2011). AKI community-based incidence has increased by 60% in the 
past few years, affecting up to 15.3% of all hospitalized patients. CKD is a major public 
health problem throughout the world. CKD affects more than 13% of the population in the 
USA and in Europe (Prunotto, 2011). The worldwide impact of CKD is significant, yet 
underestimated. According to the World Health Report 2002 and the global burden of 
disease project, kidney and urinary tract diseases contribute to 850,000 deaths per year and 
15,010,167 in disability-adjusted life years (Staples, 2010). 
Chronic kidney failure, also known as chronic renal failure, chronic renal disease, or chronic 
kidney disease, is a slow progressive loss of kidney function over a period of several years. 
The definition of CKD is kidney damage or a GFR below 60 mL per minute per 1.73 m2 for 
three months or more (National Kidney Foundation, 2004). It has been appreciated for 
several decades that once GFR has decreased below a critical level, CKD tends to progress 
relentlessly toward ESRD (Taal, 2006). Earlier recognition of CKD could slow progression, 
prevent complications, and reduce cardiovascular-related outcomes (Plantinga, 2010). Due 
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to the asymptomatic nature of this disease, CKD is not frequently detected until its later 
progress, resulting in loss of prevention opportunities. Progress to kidney failure or other 
adverse outcomes could be prevented or delayed through early detection and treatment of 
CKD (Locatelli, 2002).  
Until now the available literature exploring the epidemiology of CKD overall has not 
classified individuals according to the underlying etiology. Rather, the available population 
cohort data gathered via NHANES and the national Kidney Foundation’s KEEP have 
provided information on comorbid conditions associated with CKD, including 
hypertension, as opposed to providing accurate estimates of CKD resulting from 
hypertension; as a result, only estimates of CKD associated with hypertension can be 
provided. The 2010 USRDS report summarizes the NHANES data on CKD and comorbid 
conditions. Compared to individuals without CKD, individuals with any stage of CKD 
(stages 1–5) have higher rates of hypertension (Udani, 2011). The strong association of 
hypertension with CKD was confirmed by data from KEEP. However, the KEEP data 
suggest that hypertension is more prevalent at early stages of CKD and that individuals 
with CKD have even higher rates of hypertension than NHANES data suggest. The KEEP 
investigators found that the overall prevalence of hypertension exceeded 50% in all 
individuals with CKD, regardless of GFR, and in those with ‘normal’ renal function (GFR 
>100 ml/min/1.73 m2) the prevalence of hypertension was 57%. The two databases, 
however, included different methods of sampling individuals and, overall, have different 
demographical data (Udani, 2011). 
The attention paid globally to CKD is attributable to five factors: the rapid increase in its 
prevalence, the enormous cost of treatment, recent data indicating that overt disease is the 
tip of an iceberg of covert disease, an appreciation of its major role in increasing the risk of 
cardiovascular disease, and the discovery of effective measures to prevent its progression 
(Barsoum, 2006). Furthermore, a gender-different prevalence of CKD was revealed in most 
included studies. Females had a higher prevalence of CKD than males. Females have less 
muscle mass as compared to males and the muscle mass is a major determinant of serum 
creatinine concentration (Heimsfiled, 1983). 
Hypertension is present in more than 80% of patients with CKD and contributes to 
progression of kidney disease toward end stage (ESRD) as well as to cardiovascular events 
such as heart attack and stroke (Toto, 2005). In fact the risk for cardiovascular death in this 
patient population is greater than the risk for progression to ESRD. Proteinuria is an 
important co-morbidity in hypertensive patients with CKD and increases the risk of disease 
progression and cardiovascular events.  
3.1 Pathogenesis 
Hypertension has long been recognized as a consequence of renal impairment and an 
important factor in the progression of CKD. The RAS together with genetic background, 
renal anemia, altered mineral homeostasis, atherogenic dyslipidemia, chronic inflammation, 
and oxidative stress and others cardiovascular risk factors such as diabetes, smoking, and 
obesity are the main contributors in the pathogenesis (Wühl, 2008). CKD pathogenesis is 
characterized by a progressive loss of renal function, and an excessive deposition of 
extracellular matrix in the glomeruli and tubular interstitium (López-Novoa, 2011). Chronic 
glomerulonephritis and interstitial nephritis are currently the principal causes of CKD in 
developing countries, reflecting the high prevalence of bacterial, viral, and parasitic 
infections affecting the kidneys (Barsoum, 2006).   
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Hyperuricemia is highly prevalent in patients with CKD, reflecting reduced efficiency in 
renal excretion of uric acid associated with hypouricosuria. Evaluating the role of uric acid 
in the development or progression of CKD is difficult due to the number of confounders to 
any study (Feig, 2009). A decline in GFR is associated with increased values of serum uric 
acid because uric acid is predominantly cleared by the kidneys (Marangella, 2005). The role 
of uric acid in the initiation and progression of CKD remains controversial. Recent 
epidemiological and experimental evidence suggested that uric acid might be involved in 
the development of CKD. In animal studies, experimental hyperuricemia is associated with 
increasing proteinuria, impaired renal function, glomerulosclerosis, renal interstitial fibrosis 
and preglomerular vasculopathy (Kang, 2002). Increased renal renin expression appears to 
be involved in these adverse effects of uric acid on renal function. In humans, hyperuricemia 
also appears to be associated with activation of the intrarenal RAS (Kobori, 2007). In the 
Cardiovascular Health Study, SUA levels did not predict incident CKD but were 
independently associated with the progression of pre-existing CKD (Tziomalos, 2010). 
3.3 Assessment of kidney function 
Blood urea nitrogen and creatinine clearance are well-established biomarkers of kidney 
function that can be measured cheaply and easily (Tesch, 2010). Increases levels of serum 
creatinine are the main manifestations of hypertension-associated renal dysfunction. 
Persistent increases of serum creatinine levels reflect an important renal parenchymal 
damage and some degree of irreversible kidney dysfunction (Udani, 2011). CKD from 
glomerular disease associated with arterial hypertension can be detected by markers of renal 
parenchymal disease, like proteinuria. The evidence of early kidney injury is elusive without 
overt glomerular disease that can be found in hypertensive nephrosclerosis or early diabetic 
nephropathy. The diagnosis and staging of CKD is nowadays based upon the presence of 
signs of kidney damage together with the estimation of the GFR (Montañés, 2011).  
3.3.1 Albuminuria 
Albumin is the most abundant protein in the circulation and during normal kidney function 
very little intact albumin is excreted by the kidney (<30 mg/day in humans) (Tesch, 2010). It 
is known that a slight increase of urinary albumin excretion (microalbuminuria) is a 
predictor of renal and cardiovascular events in hypertensive patients (Hillege, 2002). 
Albuminuria is frequently used as an early marker of renal injury because it often precedes 
a decline in renal function (Tesch, 2010). In arterial hypertension, an increased 
transglomerular passage of albumin may result from several mechanisms—hyperfiltration, 
glomerular basal membrane abnormalities, endothelial dysfunction, and nephrosclerosis 
(Redon, 2002). Microalbuminuria can also be considered a marker of underlying generalized 
endothelial or vascular dysfunction. The presence of a single measurement 
microalbuminuria does not confirm the presence of glomerular disease or parenchymal 
kidney injury (Udani, 2011). A 2010 debate questioned the relevance of microalbuminuria 
measurements in the diagnosis of kidney disease and controversies regarding its use as a 
marker of CKD still exist. The results of the Avoiding Cardiovascular events through 
Combination therapy in Patients living with systolic Hypertension (ACCOMPLISH) study 
highlights the limits of microalbuminuria as a marker of kidney disease and predictor of 
CKD progression (Jamerson, 2004). 
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3.3.2 Serum creatinine and estimated glomerular filtration rate 
In clinical practice, serum creatinine became the almost universal biomarker of choice for 
GFR (Dalton, 2010). Now it appears to be a rather unreliable marker of GRF because 
creatinine serum concentrations are affected by tubular secretion, age, sex, muscle mass, 
physical activity, and diet, and therefore creatinine does not have a direct relationship with 
the GFR (Hsu, 2002). The Cockcroft-Gault and the Modification of Diet in Renal Disease 
(MDRD) equations, both based on serum creatinine, are being used increasingly because 
they overcome, at least in part, some of the limitations of creatinine measurements 
(Cockcroft, 1976; Levey, 1999). Both equations are currently recommended for the estimation 
of GFR, which is an established method for detection and classification of CKD in clinical 
practice (National Kidney Foundation, 2002). The development of formula for estimating 
GFR and disease staging based on serum creatinine reiterate the continuing importance of 
this biomarker (Dalton, 2010). 
3.3.3 Urinalysis 
Urinalysis is considered the major noninvasive diagnostic tool available to the clinician. 
Although examination of the urine can also provide some information about disease 
severity, such a direct relationship between the urinalysis and disease severity is not always 
present (Post, 2006). A normalization of the urinalysis in patients with acute 
glomerulonephritis can be considered the resolution of the active inflammatory process, a 
recovery or healing with irreversible glomerular scarring and nephron loss. In this setting, 
repeated renal biopsy may be required to accurately estimate the status of the renal disease. 
Despite potential limitations, a complete urinalysis should be performed in all patients with 
renal disease (Post, 2003). 
3.3.4 Aldosterone 
Aldosterone, the main mineralocorticoid synthesized by the adrenal gland, has an essential 
function in sodium and water homeostasis and urinary excretion of potassium (Roldán, 
2010). It is an important mediator of collagen turnover, stimulating the expression of various 
profibrotic molecules and inhibiting other antifibrotic molecules, thereby assuming a 
decisive role in the development of renal fibrosis. Aldosterone also has an important 
pathogenic role in hypertension and vascular remodeling, in left ventricular hypertrophy, 
and in renal disease, specifically proteinuria and glomerulosclerosis in patients with 
hypertension (Roldán, 2010). A lot of experimental studies analysed the damage caused by 
aldosterone in the mesangium, basement membrane, and renal tubule and indicated an 
important pathologic role of the hormone in renal function impairment. The contribution of 
aldosterone to the development of arterial hypertension in the general population has been 
shown recently by the Framingham Offspring Study in which serum plasma aldosterone 
levels in normotensive subjects predicted subsequent increases in blood pressure and in the 
development of incident hypertension (Vasan, 2004). Plasma aldosterone concentration can 
be used as a marker of impaired renal function in the initial phases of arterial hypertension 
(Roldán, 2010). 
3.3.5 Hyperhomocysteinemia 
Another marker of renal damage is hyperhomocysteinemia. Serum homocysteine 
concentrations are significantly elevated in patients with albuminuria and low GFR 
www.intechopen.com
 
Diseases of Renal Parenchyma 
 
102 
(Ikeyaga, 2005). In the Horn study, high plasma homocysteine was associated with 
microalbuminuria independently of other risk factors (Hoogeveen, 1998). Several 
biochemical mechanisms have been proposed to explain the presumed vasculotoxic effects 
of homocysteine. The main theory is that high homocysteine levels lead to endothelial 
dysfunction. Impaired endothelial vasomotor responses have been ascribed to a reduced 
bioavailability of nitric oxide due to auto-oxidation of homocysteine in plasma which leads 
to oxidative inactivation of nitric oxide (Welch, 1998). Alternatively, homocysteine may lead 
to the accumulation of asymmetric dimethylarginine by inhibiting its catabolizing enzyme 
dimethylarginine dimethylaminohydrolase (van Guldener, 2006). Hyperhomocysteinemia 
could cause subclinical renal interstitial injury, and reduced renal function promotes further 
rise in plasma homocysteine (Ikegaya, 2005). Both hyperhomocysteinemia and renal injury 
are associated as pathogenic processes, creating a vicious cycle that results in further 
impairment of renal function. 
3.3.6 Cystatin-C 
Recently, Cystatin-C, a protein member of the family of cysteine proteinase inhibitors, was 
proposed as a new reliable marker of renal function. Because of its small size, cystatin C is 
freely filtered by the glomerulus. It is not secreted but reabsorbed by tubular epithelial cells 
and subsequently catabolized so that it does not return to the blood flow (Abrahamson, 
1990). It is the product of a gene expressed in all nucleated cells and is produced at a 
constant rate, therefore permitted calculation of a cystatin C clearance using urine 
concentrations. Serum levels of cystatin C is a promising early marker of hypertension-
associated kidney dysfunction and may accurately reflect eGFR in various populations 
(Udani, 2011). The use of serum cystatin C to approximate eGFR is based on the same logic 
as the use of blood urea nitrogen and creatinine, but because it does not return to the 
bloodstream and is not secreted, the eGFR obtained may be more reflective of actual renal 
filtration function (McMurray, 2009). The cystatin C concentration is converted and reported 
in milliliters per minute giving a direct estimation of the GFR. Unlike serum creatinine, it is 
not influenced by age, sex, muscle mass, exercise or diet. A study from the Prevention of 
Renal and Vascular End-Stage Renal Disease (PREVEND) cohort found that cystatin C was 
significantly associated with C-reactive protein (CRP), smoking and body mass index, even 
after adjustment for creatinine clearance levels (Knight, 2004). The authors concluded that 
cystatin C levels were influenced by these factors in addition to kidney function. Other 
longitudinal studies have shown that cystatin C has a stronger and more linear association 
with cardiovascular disease and mortality outcomes compared to creatinine-based 
measures. These findings led to the hypothesis that cystatin C`s link to inflammation could 
explain its advantage over creatinine as a prognostic marker (Singh, 2007). 
3.3.7 Advanced Glycation End Products (AGE) 
Advanced glycation end products (AGEs) are a heterogeneous group of proteins and lipids 
covalently bound to sugar residues. It appears that activation of the RAS may contribute to 
AGE formation through various mechanisms (Bohlender, 2005). Although AGEs could 
nonspecifically bind to basement membranes and modify their properties, they also induce 
specific cellular responses including the release of profibrogenic and proinflammatory 
cytokines by interacting with the receptor for AGE (Bohlender, 2005). AGE levels are grossly 
elevated in CKD and hemodialysis as a result of decreased clearance, resulting in an 
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increased tissue accumulation. The accumulation of AGE in renal failure is even greater than 
in diabetes (Noordzij, 2008). 
3.3.8 Resistin 
Resistin, a newly discovered low molecular weight plasma protein, promotes endothelial 
dysfunction and proinflammatory activation, contributing to subclinical atherosclerosis 
(Dimitriadis, 2009). Although classified as an adipokine, resistin in humans is mainly 
produced by blood-derived leukocytes and mononuclear cells, both within and outside the 
adipose tissue (Ellington, 2007). Resistin directly induces endothelin-1 production, 
upregulates adhesion molecules and chemokines, and downregulates TNF receptor-
associated factor-3 (Verma, 2003). Resistin-induced mitochondrial dysfunction and 
imbalance in cellular redox enzymes may be the underlying mechanisms of oxidative stress 
(Chen, 2010). The humoral factors induced by resistin and their downstream effectors could 
potentiate mesangial proliferation and interstitial fibrosis, thereby affecting both glomerular 
and tubular processes. Recently, elevated levels of resistin were proposed to be a risk factor 
for kidney disease or may even represent overt kidney damage in asymptomatic adults with 
essential hypertension (Ellington, 2007).  
3.3.9 Kidney injury molecule-1 (KIM-1) 
The kidney injury molecule-1 (designated as Kim-1 in rodents, KIM-1 in humans) mRNA 
was identified using techniques of representational difference analysis, a PCR-based 
technique (Hubank, 1994; Bonventre, 2009). KIM-1 is a type 1 transmembrane protein that is 
not detectable in normal kidney tissue but is expressed at high levels in human and rodent 
kidneys with dedifferentiated proximal tubule epithelial cells after ischemic or toxic injury 
(Han, 2005).  KIM-1 is strongly up-regulated in dedifferentiated proximal tubule kidney 
epithelial cells after an ischemic or toxic injury. It may also play a role in epithelial adhesion, 
growth, and differentiation (Malyszko, 2010). KIM-1 not only functions as a biomarker but 
also has predictive value for acute renal injury, but was predictive for adverse clinical 
outcome in a cohort of 201 hospitalized patients with acute renal failure (Lock, 2010). 
Urinary Kim-1 levels may serve as a noninvasive, rapid, sensitive, reproducible, and 
potentially high-throughput method to detect early kidney injury in pathophysiological 
studies and in preclinical drug development studies for risk-benefit profiling of 
pharmaceutical agents (Vaidya, 2006). 
3.3.10 Asymmetric dimethylarginine 
Asymmetric dimethylarginine (ADMA) is a naturally occurring L-arginine analogue, found 
in plasma and various types of tissues, acting as an endogenous NO synthase inhibitor in 
vivo (Ueda, 2007). Further, plasma level of ADMA is elevated in patients with CKD and 
found to be a strong biomarker or predictor for future cardiovascular events (Ueda, 2007). In 
addition, plasma level of ADMA could predict the progression of renal injury in these 
patients, as well. These findings suggest that elevation of ADMA may be a missing link 
between CVD and CKD. ADMA levels are markedly elevated in renal impairment, together 
with the experimental evidence showing ADMA to be a CKD progression factor in animals; 
four prospective studies have found an association between ADMA level and CKD 
progression in humans (Kronenberg, 2009). 
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3.3.11 Interleukin-18 (IL-18) 
Interleukin-18 (IL-18) is a proinflammatory cytokine which is induced in PCT and is 
detected in urine following AKI. It was found to be an early predictor of AKI in patients 
with adult respiratory distress syndrome with an area under the curve (AUC) of 0.73 (Soni, 
2009). It was also found to be an independent predictor of mortality in this study. In another 
study on patients undergoing cardiac surgery, urinary IL-18 levels increased 6 h after 
cardiopulmonary bypass (CPB) and peaked at 12 h in patients who were diagnosed to have 
AKI 2 days later by creatinine criteria (Han, 2009). Elevated urinary IL-18 is more specific for 
ischemic AKI and its levels are not deranged in CKD, urinary tract infections or nephrotoxic 
AKI. However, a study by Haase et al. did not find IL-18 to be a useful early predictor of 
AKI in a group of 100 adult patients undergoing cardiac surgery (Soni, 2009). 
3.3.12 Urinary Netrin-1 (Ntn-1) 
Netrin-1 (Ntn-1), a laminin-related axon guidance molecule, is highly induced and excreted 
in the urine after acute kidney injury (AKI) in animals (Ramesh, 2010). Previous studies 
proved that Ntn-1 is involved in the orchestration of inflammatory responses in vitro or in 
vivo (Ly, 2005; Rosenberger, 2009). The kidney has one of the highest levels of netrin-1 
expression, and administration of recombinant netrin-1 before ischemia reperfusion reduces 
kidney injury and inflammation (Wang, 2008). 
3.3.13 Urinary neutrophil gelatinase-associated lipocalin (NGAL) 
Urinary neutrophil gelatinase-associated lipocalin (NGAL) is a small (25 kDa) protein, 
expressed in renal tubular cells and released into the blood and urine after exposure to 
ischemia or toxicity (Devarajan, 2010) and represent a promising new renal biomarker able 
to diagnose acute kidney injury (AKI). It is rapidly induced and released from the injured 
renal distal nephrons in experimental studies and various human diseases. The changes of 
body water content could, thus, influence the urinary concentration, like for other urinary 
biomarkers, too. The release of NGAL occurs within hours after the stimulus and long 
before an increase in serum creatinine level. Urinary and plasma concentrations of NGAL 
increase proportionally to severity and duration of renal injury and rapidly decrease with its 
attenuation. However, NGAL release is not specific to the kidney. Measurements may be 
readily and easily performed in urine and plasma using clinical laboratory platforms or 
point of care devices (Haase, 2011). Therefore, the NGAL level was proposed to be a real-
time indicator of active kidney damage, whereas creatinine level and GFR are markers of 
functional nephron number (Kronenberg, 2009). 
3.3.14 Liver-type fatty acid binding protein (L-FABP) 
Clinical data on associations between liver-type fatty acid binding protein (L-FaBP) and 
kidney disease are sparse (Kronenberg, 2009). This protein is expressed in proximal tubular 
cells and increased expression and higher levels are seen in the urine of patients with kidney 
disease and is considered a promising indicator of tubular but not glomerular damage 
(Kamijo-Ikemori, 2011). A large health screening program in more than 900 individuals 
revealed that average urinary levels of L-FaBP were approximately 50% higher in patients 
with diabetes mellitus, hypertension or chronic hepatitis than in controls. A study 
investigating L-FaBP levels in patients with type 2 diabetes and different stages of 
nephropathy showed that urinary L-FaBP was associated with the severity of diabetic 
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nephropathy (Nakamura, 2005). Small studies in patients with mild kidney dysfunction 
suggest that urinary L-FaBP concentrations are increased in patients whose renal function 
deteriorates further (Kamijo, 2004). 
3.4 Lifestyle modifications 
In the general population, the strategies that lower blood pressure include dietary and 
lifestyle modifications in order to prevent and treat arterial hypertension. Blood pressure 
and CKD management rely heavily upon the patient's ability to self-manage and willingness 
to change or maintain health-promoting behaviors. The prevalence of hypertension may be 
also reduced also by measures like eight loss, sodium restriction, fluid restriction, exercise, 
and limitation of alcohol intake (Miller, 2003).  
The Intersalt Cooperative Research Study, which measured urinary sodium in over 10,000 
individuals from 32 countries, found that consumption of more than 100 mmol/day sodium 
was associated with significantly higher blood pressures (Miller, 2003). Sodium restriction is 
also a crucial component to dietary intake for patients with CKD. In CKD, extracellular 
volume expansion as a result of impaired natriuresis is thought to play an important role in 
the pathogenesis of hypertension. It is therefore recommended that dietary sodium intake 
should be less than 100 mmol/day. Exercise and weight loss (if body mass index is more 
than 25 kg/m2) are also recommended (Thuraisingham, 2011). 
The Dietary Approaches to Stop Hypertension (DASH) diet has been shown to produce 
most benefits in blood pressure reduction through sodium restriction and weight loss,  
and can also decrease LDL cholesterol. The DASH diet is a result of a feeding study of 459 
adults (49% women, 60% African American) with high normal or elevated blood pressure 
(Sacks, 2001). 
3.5 Pharmacologic intervention 
The discussed pathophysiology of hypertensive renal damage suggests three broad targets 
for therapeutic interventions: (1) reduction of BP load; (2) reduction of pressure transmission 
to the renal microvasculature; and (3) interruption and/or modification of the local 
cellular/molecular pathways that mediate eventual tissue injury and fibrosis (Bidani, 2004). 
Antihypertensive therapy significantly decreases the vascular damage in the kidneys of 
hypertensive patients. Therapy of hypertension is therefore imperative. The National 
Kidney Foundation clinical practice guidelines recommend a blood pressure goal of <130 
mmHg systolic and <80 mmHg diastolic for all CKD patients. Post-hoc analyses of the 
Modification of Diet in Renal Disease study indicate that lower blood pressure may provide 
long-term kidney protection in patients with nondiabetic kidney disease. Specifically a mean 
arterial pressure < 92 mmHg (e.g. 120/80 mmHg) compared to 102-107 mmHg (e.g. 140/90 
mmHg) is associated with a reduced risk for ESRD (Toto, 2005). Citing KDOQI, the seventh 
report from the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7) also recommends a target BP of < 130/80 mmHg 
for all patients with CKD defined as an GFR<60 ml/min per 1.73m 2 or protein-to-creatinine 
ratio ≥ 200 mg/g.1 A target BP < 130/80 mmHg is also recommended by the American 
Diabetes Association (ADA) and by JNC 7 for all patients with diabetes (O’Hare, 2009). 
The inhibition of the effects of angiotensin II is necessary to ensure the best degree of renal 
protection by the simultaneous control of blood pressure (BP) and the achievement of the 
maximal antiproteinuric capacity. The inhibition can be attained through the administration 
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of either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor 
blocker (ARB). Uptitration of antihypertensive therapy is frequently required to achieve the 
desired BP goal in patients presenting with renal disease, with or without proteinuria. 
Control of BP is good for both cardiovascular and renal protection (Segura, 2003).  
RAS inhibitors have been shown to reduce proteinuria and the rate of loss of renal function 
in patients with CKD (Ito, 2010). However, the benefits of RAS inhibition seem to depend on 
the degree of proteinuria at baseline. Namely, RAS inhibition has been shown to be 
beneficial in patients with at least 0.5 g per day proteinuria, whereas no convincing evidence 
exists to demonstrate the benefits extended to patients with a lower level of proteinuria 
(Jafal, 2001). An “adequate” BP control with standard antihypertensive therapy, the kidney 
is well protected and very few hypertensive patients, less than 2%, will develop renal 
damage as a consequence of arterial hypertension (Ruilope, 2002). Interestingly, data from 
the ACCOMPLISH trial demonstrated that use of an ACE inhibitor in combination with a 
calcium antagonist was associated with a reduced requirement for dialysis than use of an 
ACE inhibitor and a diuretic in individuals > 65 years of age (Backris, 2010). 
Identifying individuals with early signs of CKD might help the targeting of therapies to 
more effectively prevent disease progression and associated complications. Identifying an 
appropriate marker of early renal dysfunction, however, remains challenging and depends 
on the underlying etiology of kidney disease.  Early diagnosis on the basis of presence of 
proteinuria or reduced estimated GFR could permit early intervention to reduce the risks of 
cardiovascular events, kidney failure, and death that are associated with chronic kidney 
disease. In developed countries, screening for the disorder is most effective when targeted at 
high-risk groups including elderly people and those with concomitant illness (such as 
diabetes, hypertension, or cardiovascular disease) or a family history of chronic kidney 
disease, although the role of screening in developing countries is not yet clear. Different 
strategies available now aimed to slow the progression of CKD and to reduce cardiovascular 
risk (James, 2010). Treatment of high blood pressure is recommended for all individuals 
with, or at risk of, chronic kidney disease. Use of angiotensin-converting-enzyme inhibitors 
or angiotensin-receptor blockers is preferred for patients with diabetic CKD or those with 
the proteinuric non-diabetic disorder (Matthew, 2010). 
4. Conclusion 
In conclusion, hypertension-associated renal damage would paradoxically originate from 
subtle, focal renovascular damage, where hypertension would be another mere consequence 
acting as a magnifying amplifier in the vicious circle of malignancy. The therapeutic strategy 
aims, at targeting the pathophysiological processes mentioned in this chapter, to prevent, 
reduce or reverse the renal organ damage due to arterial hypertension.  
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